Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.18 +5.9%	$1.49	$1.05 ▼ $10.16	$36.84M	1.88	238,983 shs	596,678 shs
APRE Aprea Therapeutics	$1.87 +4.0%	$1.69	$1.41 ▼ $5.01	$10.36M	1.18	22,849 shs	29,981 shs
COEP Coeptis Therapeutics	$9.21 -1.0%	$9.52	$2.31 ▼ $13.70	$32.36M	-0.66	117,267 shs	7,884 shs
ONCY Oncolytics Biotech	$0.34 -0.4%	$0.51	$0.33 ▼ $1.53	$29.67M	1	576,898 shs	324,140 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+0.91%	-5.13%	-21.28%	-79.29%	-85.62%
APRE Aprea Therapeutics	+1.12%	+7.78%	-2.70%	-29.41%	-62.26%
COEP Coeptis Therapeutics	+0.76%	-10.66%	+14.11%	-15.45%	+71.97%
ONCY Oncolytics Biotech	-2.71%	-17.78%	-37.45%	-47.08%	-67.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	3.8125 of 5 stars	4.5	3.0	2.7	3.3	0.6
APRE Aprea Therapeutics	3.5762 of 5 stars	3.5	4.0	3.3	2.5	1.3
COEP Coeptis Therapeutics	1.1304 of 5 stars	0.0	5.0	2.5	1.7	0.0
ONCY Oncolytics Biotech	1.7694 of 5 stars	3.4	2.0	3.8	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,407.60% Upside
APRE Aprea Therapeutics	3.00	Buy	$15.50	727.77% Upside
COEP Coeptis Therapeutics	2.00	Hold	N/A	N/A
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	1,164.47% Upside

Current Analyst Ratings Breakdown

Latest APRE, ACRV, COEP, and ONCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/26/2025	ACRV Acrivon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/26/2025	ACRV Acrivon Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00
3/25/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
3/10/2025	ONCY Oncolytics Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
3/10/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.38 per share	N/A
APRE Aprea Therapeutics	$580K	17.86	N/A	N/A	$4.54 per share	0.41
COEP Coeptis Therapeutics	$62.87K	514.74	N/A	N/A	$0.48 per share	19.19
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$60.39M	-$2.22	N/A	N/A	N/A	N/A	-47.95%	-43.73%	8/12/2025 (Estimated)
APRE Aprea Therapeutics	-$14.29M	-$2.37	N/A	N/A	N/A	-1,029.50%	-57.86%	-47.94%	8/11/2025 (Estimated)
COEP Coeptis Therapeutics	-$21.27M	-$5.80	N/A	∞	N/A	N/A	-1,094.50%	-219.97%	N/A
ONCY Oncolytics Biotech	-$20.56M	-$0.29	N/A	N/A	N/A	N/A	-141.15%	-84.73%	7/30/2025 (Estimated)

Latest APRE, ACRV, COEP, and ONCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	APRE Aprea Therapeutics	-$0.6543	-$0.66	-$0.0057	-$0.66	N/A	$0.16 million
5/14/2025	Q1 2025	COEP Coeptis Therapeutics	N/A	-$1.11	N/A	-$1.11	N/A	N/A
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
3/27/2025	Q4 2024	ACRV Acrivon Therapeutics	-$0.69	-$0.60	+$0.09	-$0.60	N/A	N/A
3/25/2025	Q4 2024	APRE Aprea Therapeutics	-$0.69	-$0.49	+$0.20	-$0.49	$0.15 million	$0.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	12.75	12.75
APRE Aprea Therapeutics	N/A	7.28	7.28
COEP Coeptis Therapeutics	0.03	0.40	0.40
ONCY Oncolytics Biotech	N/A	2.99	2.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
APRE Aprea Therapeutics	34.19%
COEP Coeptis Therapeutics	13.88%
ONCY Oncolytics Biotech	6.82%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
APRE Aprea Therapeutics	12.80%
COEP Coeptis Therapeutics	24.25%
ONCY Oncolytics Biotech	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.36 million	28.49 million	Not Optionable
APRE Aprea Therapeutics	7	5.53 million	4.74 million	No Data
COEP Coeptis Therapeutics	2	3.51 million	2.46 million	Not Optionable
ONCY Oncolytics Biotech	30	86.58 million	85.42 million	Not Optionable

APRE, ACRV, COEP, and ONCY Headlines

Recent News About These Companies

Q2 EPS Estimates for Oncolytics Biotech Cut by HC Wainwright

May 25, 2025 | americanbankingnews.com

HC Wainwright Reaffirms "Buy" Rating for Oncolytics Biotech (NASDAQ:ONCY)

May 24, 2025 | americanbankingnews.com

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 23, 2025 | prnewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunome (IMNM), Oncolytics Biotech (ONCY) and Hookipa Pharma (HOOK)

May 18, 2025 | theglobeandmail.com

Jones Trading Downgrades Oncolytics Biotech (ONCY)

May 17, 2025 | msn.com

Oncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter Financial Results and Highlights Clinical Momentum

May 17, 2025 | finanznachrichten.de

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 14, 2025 | prnewswire.com

Oncolytics Biotech to Discuss Q1 2025 Financial Results on May 14

May 8, 2025 | tipranks.com

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

May 6, 2025 | prnewswire.com

Oncolytics Biotech, Inc. Common Shares (ONCY) Latest After Hours Trades

May 4, 2025 | nasdaq.com

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

April 24, 2025 | prnewswire.com

As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments

April 14, 2025 | baystreet.ca

Oncolytics Biotech Secures $20 Million Funding for Pelareorep Development

April 10, 2025 | tipranks.com

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

April 10, 2025 | prnewswire.com

Oncolytics Biotech® and Pelareorep Discussed During

April 10, 2025 | kxan.com

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

April 10, 2025 | prnewswire.com

Oncolytics price target lowered to $3 from $5 at Maxim

March 10, 2025 | markets.businessinsider.com

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Earnings Call Transcript

March 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, ACRV, COEP, and ONCY Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.18 +0.07 (+5.86%)

As of 12:39 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Aprea Therapeutics NASDAQ:APRE

$1.87 +0.07 (+4.03%)

As of 12:24 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Coeptis Therapeutics NASDAQ:COEP

$9.21 -0.09 (-0.97%)

As of 12:30 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Oncolytics Biotech NASDAQ:ONCY

$0.34 0.00 (-0.38%)

As of 12:40 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time